中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.041 seconds)

    Methods and species-specific primers for detection and quantification of Streptococcus mutans and Streptococcus sanguinis in mixed bacterial samples
    4.
    发明申请
    Methods and species-specific primers for detection and quantification of Streptococcus mutans and Streptococcus sanguinis in mixed bacterial samples 审中-公开
    在混合细菌样品中检测和定量变异链球菌和血链球菌的方法和物种特异性引物

    公开(公告)号：US20090305252A1

    公开(公告)日：2009-12-10

    申请号：US12156955

    申请日：2008-06-04

    Applicant: Yihong Li ,  Page W. Caufield ,  Deepak Saxena ,  Zhou Chen

    Inventor： Yihong Li ,  Page W. Caufield ,  Deepak Saxena ,  Zhou Chen

    IPC: C12Q1/68 ,  C07H21/00

    CPC classification number: C12Q1/689 ,  C12Q2600/16

    Abstract: Dental caries is a polymicrobial infectious disease. Of the hundreds of bacteria present in the biofilms coating teeth, the Streptococcus mutans (S. mutans) remain strongly linked to caries and dental disease. Streptococcus sanguinis (S. sanguinis) may serve a protective or antagonistic role against the cariogenic bacterium S. mutans. In the present invention, exemplary sets of species-specific PCR primers are provided for the identification and quantification of S. mutans and of S. sanguinis in clinical samples, including the simultaneous and sensitive analysis of both bacterial species. Assays, kits and methods for determining the presence and amount of S. mutans and/or S. sanguinis are provided. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods for determining and evaluating an individual's oral bacteria, risk for caries, and effects of prevention and treatment modalities, are provided.

    Abstract translation: 牙龋是一种多微生物感染性疾病。 在生物膜涂覆牙齿中存在的数百种细菌中，变形链球菌（变形链球菌）与龋齿和牙齿疾病密切相关。 血清链球菌（S.sanguinis）可能对致龋菌细菌变形链球菌起保护作用或拮抗作用。 在本发明中，提供了典型的物种特异性PCR引物组用于在临床样品中鉴定和定量变形链球菌和血清芽孢杆菌，包括对这两种细菌物种的同时和敏感的分析。 提供了用于确定变形链球菌和/或血清血友病的存在和量的测定，试剂盒和方法。 描述了用于测定，试剂盒和方法的寡核苷酸探针和引物。 提供了确定和评估个人口腔细菌，龋风险和预防和治疗方式的影响的方法和方法。

    Urea linker derivatives for use as PPAR modulators
    6.
    发明授权
    Urea linker derivatives for use as PPAR modulators 失效
    用作PPAR调节剂的尿素接头衍生物

    公开(公告)号：US06984661B2

    公开(公告)日：2006-01-10

    申请号：US10500489

    申请日：2003-01-21

    Applicant: James Robert Henry ,  YiHong Li

    Inventor： James Robert Henry ,  YiHong Li

    IPC: A61K31/36 ,  A61K31/195 ,  C07D317/44 ,  C07C323/63 ,  C07C275/28

    CPC classification number: C07C275/36 ,  C07C275/10 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/38 ,  C07C2601/14 ,  C07C2602/08 ,  C07D317/66

    Abstract: The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl substituted C1-C8 alkyl, aryl-C0-4-alkyl, substituted aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, substituted heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and substituted C3-C6 cycloalkylaryl-C0-2-alkyl; (b) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH2)n COOR19 and substituted (CH2)n COOR19.

    Abstract translation: 本发明涉及结构式（I）的化合物及其药学上可接受的盐，溶剂合物和水合物：式I（a）R 1，R 2和R 6各自独立地选自氢，C 1 -C 6烷基， 1个C 1 -C 8烷基取代的C 1 -C 8烷基，芳基-C 0-4

    Urea linker derivatives for use as ppar modulators
    10.
    发明申请
    Urea linker derivatives for use as ppar modulators 失效
    用作ppar调节剂的尿素连接体衍生物

    公开(公告)号：US20050004183A1

    公开(公告)日：2005-01-06

    申请号：US10500489

    申请日：2003-01-21

    Applicant: James Henry ,  YiHong Li

    Inventor： James Henry ,  YiHong Li

    IPC: C07D317/68 ,  A61K31/195 ,  A61K31/36 ,  A61P3/10 ,  A61P43/00 ,  C07C275/10 ,  C07C275/24 ,  C07C275/26 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/36 ,  C07C275/38 ,  C07D317/66 ,  A61K31/175 ,  A61K31/17 ,  A61K31/40 ,  A61K31/44 ,  C07D213/42

    CPC classification number: C07C275/36 ,  C07C275/10 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/38 ,  C07C2601/14 ,  C07C2602/08 ,  C07D317/66

    Abstract: The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl substituted C1-C8 alkyl, aryl-C0-4-alkyl, substituted aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, substituted heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and substituted C3-C6cycloalkylaryl-C0-2-alkyl; (b) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH2)n COOR19 and substituted (CH2)n COOR19.

    Abstract translation: 本发明涉及结构式（I）的化合物及其药学上可接受的盐，溶剂合物和水合物：式I（a）R 1，R 2和R 6各自独立地选自氢，C 1 -C 8烷基 取代的C 1 -C 8烷基，芳基-C 0-4 - 烷基，取代的芳基-C 0-4 - 烷基，杂芳基-C 0-4 - 烷基，取代的杂芳基-C 0-4 - 烷基，C 3 -C 6环烷基芳基-C 0-2 - 烷基 和取代的C 3 -C 6环烷基芳基-C 0-2 - 烷基; （b）X是任选取代的C1-C5亚烷基连接体，其中连接体的一个碳原子可被O，NH或S取代; （c）Y是C，O，S，NH或单键; 和（d）E选自氢，C（R 3）（R 4）A，A，（CH 2）n COOR 19和取代的（CH 2）n COOR 19）。

Patent Agency Ranking